Files in this item

FilesDescriptionFormat

application/pdf

application/pdfscience.aal4222.pdf (288kB)
(no description provided)PDF

Description

Title:CRISPR, Surrogate Licensing, and Scientific Discovery
Author(s):Contreras, Jorge L.; Sherkow, Jacob S.
Subject(s):Intellectual Property
Patent
Biotech
Biotechnology
CRISPR
Genetics
Surrogate
Licensing
Spinoff
Abstract:Several research institutions are embroiled in a legal dispute over the foundational patent rights to CRISPR-Cas9 gene-editing technology, and it may take years for their competing claims to be resolved. But even before ownership of the patents is finalized, the institutions behind CRISPR have wasted no time capitalizing on the huge market for this groundbreaking technology by entering into a series of licensing agreements with commercial enterprises. With respect to the potentially lucrative market for human therapeutics and treatments, each of the key CRISPR patent holders has granted exclusive rights to a spinoff or "surrogate" company formed by the institution and one of its principal researchers. Although this model, in which a university effectively outsources the licensing and commercialization of a valuable patent portfolio to a private company, is not uncommon in the world of university technology transfer, we suggest it could rapidly bottleneck the use of CRISPR technology to discover and develop useful human therapeutics.
Issue Date:2017-02-17
Publisher:Science
Citation Info:Jorge L. Contreras & Jacob S. Sherkow, CRISPR, Surrogate Licensing and Scientific Discovery, 355 Science 698 (2017)
Genre:Article
Type:Text
Language:English
URI:http://hdl.handle.net/2142/110973
DOI:10.1126/science.aal4222
Date Available in IDEALS:2021-09-17


This item appears in the following Collection(s)

  • Illinois Research and Scholarship
    This is the default collection for all research and scholarship developed by faculty, staff, or students at the University of Illinois at Urbana-Champaign

Item Statistics